



## InvestorMeet

# Licensing deal with Stalicia SA Clinical Programme update

October 2022





THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, JAPAN, NEW ZEALAND AND THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This document and the related verbal presentation (together the "Presentation") are for your information only, and are being delivered by Evgen Pharma plc (the "Company" or "Evgen") which trades on the AIM market of the London Stock Exchange under ticker EVG.

By attending this Presentation, you agree to be bound by the following conditions. Please note that the information in this Presentation has yet to be announced or otherwise made public and some or all of the information in this Presentation or any discussion surrounding the Presentation may constitute inside information relating to the securities of the Company within the meaning of the insider dealing provisions of the Criminal Justice Act 1993 and/or of the EU Market Abuse Regulation (Regulation 596/2014) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). By accepting this Presentation the recipient agrees to comply with its obligations under the MAR, including by not making use of any of inside information for the purpose of dealing, or of counselling or procuring any other person to deal, in the securities of the Company. The information and opinions contained in this Presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this Presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this and any errors therein or omissions therefrom.

This document is not an admission document or a prospectus. This document does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. This Presentation has not been authorised or approved for the purposes of section 21 of the Financial Services and Markets Act 2000 and therefore it is being delivered for information purposes within (a) the United Kingdom only to persons (i) who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or are high net worth entities falling within Article 49(2)(a) to (d) of the Order and investment personnel of any of the foregoing (each within the meaning of the Order); and (ii) who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("Qualified Investors"); and (iii) to whom the Presentation may otherwise lawfully be communicated; (b) the European Economic Area (the "EEA") only to Qualified Investors (all such persons together being referred to as "Relevant Persons" and each a "Relevant Person"). By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a Relevant Person and agrees to be bound by the following conditions. This Presentation is not to be disclosed to any other person or used for any other purpose.

If you are in any doubt about the contents of this document, you should consult a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on the acquisition of shares and securities of unlisted companies. You should be aware that an investment in the Company involves a high degree of risk and investors should be aware of such risks and should rely on their own examination of the Company and make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

The distribution of this Presentation in certain jurisdictions may be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by the Company or any other person. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation. No part of this Presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or any transaction to be entered into by any member of the Evgen group. No undertaking, representation or warranty, express or implied, is given by the Company, any member of the Evgen group, or any of their respective current or proposed directors, officers, partners, employees, secondees, agents or advisers or any other person as to the accuracy or completeness of the information or as to the opinions contained in this document and no liability is accepted for any such information or opinions. Further, the information in this Presentation is not complete and may be changed. Recipients of this Presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this document and should make such other investigations as they deem necessary.


This Presentation may contain forward-looking statements that reflect the Company's current views and expectations regarding future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These forward-looking statements include matters that are not historical facts and speak only as of the date of this Presentation. They appear in a number of places throughout this document and include statements regarding the Company and the directors, and the directors' current intentions, beliefs or expectations concerning, amongst other things, to management's strategic vision, aims and objectives, the conduct of clinical trials, the filing dates for product licence applications and the anticipated launch of specified products in various markets, the Company's ability to find partners for the development and commercialisation of its products as well as the terms for such partnerships, anticipated levels of demand for existing products and products in development, the effect of competition, anticipated efficiencies, trends in results of operations, margins, the overall pharmaceutical market and exchange rates, are all forward looking in nature.

# Evgen - A Clinical Stage Drug Development Company

Focus on breast cancer, glioma and other cancers

SFX-01 has three molecular targets, STAT 3, Nrf2 and SHP2

- Developing a new class of pharmaceuticals - based on highly biologically active “sulforaphane” - applications in multiple therapeutic areas based on a network of targets
- Strong third party pre-clinical and clinical data on sulforaphane
- Four target diseases in cancer and inflammation, each with high unmet clinical needs
- Unique platform technology – Sulforadex<sup>®</sup>, stabilises unstable sulforaphane, lead SFX-01
- Strong, granted IP covering composition, manufacturing and novel derivatives
- Highly experienced board and management
- Business model: establish proof of concept and partner. Multiple value inflection points
- £9.0m in cash as at 31 March 2022




# Terms of licensing deal with Stalicla SA



Exclusive, global license to develop and commercialise SFX-01 in neurodevelopmental disorders and schizophrenia

- Milestone payments up to commercial launch of \$26.5m - \$6m forecast by ca. end 2023
- Total milestones of \$160.5m
- Royalties on sales are in low to medium double-digit range in all scenarios
- Initial indication is Autism Spectrum Disorder (ASD)
- Stalicla will fund all clinical development activities



# Autism Spectrum Disorder

- Currently no approved treatments
- Circa 1.7 million people with the condition in the USA\*
- US market for therapeutics in 2021 was almost \$4bn\*\*
- Increasing incidence worldwide
- Supportive regulatory environment to fast-track therapeutic development programmes

\* GlobalData

\*\* Fortune Business Insights

# Rationale for SFX-01 in ASD


- Encouraging data in 2014 clinical trial of sulforaphane in ASD patients
- ASD patient population is very heterogeneous
- Stalicta has a unique, proprietary technology to identify ASD patients who are most likely to respond to SFX-01.
- This screening approach is already validated as identifying patients likely to respond to treatment in other ASD drug trials
- Reduces clinical development risk and may bring a therapeutic option to individuals who are currently underserved

# HV study and GBM programme

- HV, PK/PD study open for recruitment
- GBM regulatory scientific advice received in the Netherlands, supportive
- First GBM study to be conducted as an ISS led by Erasmus University, Rotterdam
- Resulting cash runway to at least Q4 2024; well into 2025 if Stalicia milestones are included



# Our Pipeline





Evgen Pharma Plc  
enquiries@evgen.com  
[www.evgen.com](http://www.evgen.com)





# Stalicia



A privately held Swiss company with large and well-funded shareholders

- Stalicia is a precision medicine clinical stage biotech company
- Strong management team with relevant Big Pharma backgrounds
- Advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), and Neuropsychiatric Disorders
- The DEPI platform has been validated in clinical setting showing high specificity, sensitivity and positive predictive value

